WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis

References

• Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868–876
   PubMed Web of Science ®Google Scholar
• Hohenstein P, Hastie N D. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genetics 2006; 15: R196–R201
   PubMed Web of Science ®Google Scholar
• Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product. Sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004; 12: 122–126
   PubMedGoogle Scholar
• Acs G, Pasha T, Zhang P J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004; 23: 110–118
   PubMed Web of Science ®Google Scholar
• Hylander B, Repasky E, Shrikant P, et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 2006; 101: 12–17
   PubMed Web of Science ®Google Scholar
• Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109–115
   PubMed Web of Science ®Google Scholar
• Hashi A, Yuminamochi T, Murata S, et al. Wilms gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 2003; 22: 374–377
   PubMed Web of Science ®Google Scholar
• Nakatsuka S-i, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804–814
   PubMed Web of Science ®Google Scholar
• Waldstrom M, Grove A. Immunohistocheical expression of Wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 2005; 129: 85–88
   PubMed Web of Science ®Google Scholar
• Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wims' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158–163
   PubMed Web of Science ®Google Scholar
• Hogdall E VS, Christensen L, Kjaer S K, et al. Expression of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer from the Danish ‘MALOVA’ study. Gynecol Oncol 2007; 106: 318–324
   PubMed Web of Science ®Google Scholar
• Logani S, Oliva E, Amin M B, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers. Histogenetic and diagnostic implications. Am J Surg Pathol 2003; 27: 1434–1441
   PubMed Web of Science ®Google Scholar
• Cathro H P, Stoler M H. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 2005; 36: 195–201
   PubMed Web of Science ®Google Scholar
• Goldstein N S, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001; 116: 246–252
   PubMed Web of Science ®Google Scholar
• Lee B H, Hecht J L, Pinkus J L, Pinkus G S. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002; 117: 745–750
   PubMed Web of Science ®Google Scholar
• Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005; 29: 1482–1489
   PubMed Web of Science ®Google Scholar
• Zhu W, Michael C W. WT1, monoclonal CEA, TTF-1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007; 35: 370–375
   PubMed Web of Science ®Google Scholar
• Euscher E D, Malpica A, Deavers M T, et al. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 2005; 29: 1074–1078
   PubMed Web of Science ®Google Scholar
• Goldstein N S, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002; 117: 541–545
   PubMed Web of Science ®Google Scholar
• McCluggage W G. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004; 23: 97–99
   PubMed Web of Science ®Google Scholar
• Golstein N S. WT-staining in endometrial serous carcinomas. Int J Gynecol Pathol 2004; 23: 405–412
   PubMed Web of Science ®Google Scholar
• Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous carcinoma: an immunohistochemical study. BMC Cancer 2006; 6: 90
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tsuda H, Kita T, et al. Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 2007; 451: 27–35
   PubMed Web of Science ®Google Scholar
• Hutchings Y, Osada T, Woo C Y, et al. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 2007; 9: 62–69
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 2005; 4: 503–512
   PubMed Web of Science ®Google Scholar
• McCluggage W G. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008; 61: 152–163
   PubMed Web of Science ®Google Scholar
• Prefumo F, Venturini P L, Fulcheri E. Analysis of p53 and c-erbB-2 expression in ovarian endometrioid carcinomas arising in ovarian endometriosis. Int J Gynecol Pathol 2002; 22: 83–88
   Web of Science ®Google Scholar
• Maheswaran S, Englert C, Bennett P, et al. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Develop 1995; 9: 2143–2156
   PubMed Web of Science ®Google Scholar
• Benedet J L, Bender H, Jones III H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 2000; 70: 209–262
   PubMed Web of Science ®Google Scholar
• Robboy S J, Dano M B. Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries?. Hum Pathol 2005; 36: 597–599
   PubMed Web of Science ®Google Scholar
• Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129–137
   PubMed Web of Science ®Google Scholar
• Murray S K, Clement P B, Young R H. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005; 29: 157–166
   PubMed Web of Science ®Google Scholar
• Cramer S F, Roth L M, Ulbright T M, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. Arch Pathol Lab Med 1987; 111: 819–829
   PubMed Web of Science ®Google Scholar
• Tyler C W, Lee N C, Robboy S J, et al. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?. Am J Obstet Gynecol 1991; 164: 65–70
   PubMed Web of Science ®Google Scholar
• Gilks C B. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200–205
   PubMed Web of Science ®Google Scholar
• Coosemans A, Amini Nik A, Caluwaerts S, et al. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 2007; 43: 1630–1637
   PubMed Web of Science ®Google Scholar
• Feeley K M, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38: 87–95
   PubMed Web of Science ®Google Scholar
• Bell D A. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18: S19–S32
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Amant F, Neven P, et al. Endometriosis and the develpoment of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18: 349–371
   PubMed Web of Science ®Google Scholar
• Wells M. Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. Int J Gynecol Pathol 2004; 23: 316–320
   PubMed Web of Science ®Google Scholar
• Bell K A, Kurman R J. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000; 24: 1465–1479
   PubMed Web of Science ®Google Scholar
• Roth L M, Emerson R E, Ulbright T M. Ovarian endometrioid tumors of low malignant potential. A clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol 2003; 27: 1253–1259
   PubMed Web of Science ®Google Scholar
• Swiersz L M. Role of endometriosis in cancer and tumor development. Ann NY Acad Sci 2002; 955: 281–292
   PubMed Web of Science ®Google Scholar
• Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360–1368
   PubMed Web of Science ®Google Scholar
• Young R H, Prat J, Scully R E. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors: a clinicopathologic analysis of 13 cases. Am J Surg Pathol 1982; 6: 513–522
   PubMed Web of Science ®Google Scholar
• Aguirre P, Thor A D, Scully R E. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. Int J Gynecol Pathol 1989; 8: 364–373
   PubMed Web of Science ®Google Scholar
• Guerrieri C, Franlund B, Malmstrom H, Boeryd B. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int J Gynecol Pathol 1998; 17: 266–271
   PubMed Web of Science ®Google Scholar
• Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol 1998; 29: 840–849
   PubMed Web of Science ®Google Scholar
• Liang S X, Patel K, Pearl M, et al. Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review. Int J Gynecol Pathol 2007; 26: 291–297
   PubMed Web of Science ®Google Scholar